As shown in Fig. 3b, 4.8% of hTS/Ink4a/Arf−/− with STS were diagnosed with LS, endometrial stromal sarcoma (ESS) or LMS and 9.6% with RMS. The gene discussed is CDKN2A; the disease is endometrioid stromal sarcoma.